Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance
DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.
Financial and operating highlights during the first quarter of fiscal 2018 include:
-
Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year. U.S. revenue from Impella heart pumps grew 28% to $114.7 million and U.S. Impella patient usage grew 27%.
-
Outside the U.S., revenue from Impella heart pumps totaled $12.5 million and was up 53%, predominately from Germany, which grew 62% in revenue from the prior fiscal year.
-
The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 16 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,154 sites. The installed customer base for Impella CP® heart pumps grew by 46 new U.S. hospitals, bringing the total number of Impella CP sites to 1,062. The installed customer base for Impella 5.0® heart pumps grew by 19 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 472.
-
An additional 15 sites made initial purchases of the Impella RP® heart pumps during the quarter, bringing the total number to 142 sites.
-
Gross margin for fiscal first quarter 2018 was 83.5% compared to 85.4% in the first quarter of fiscal 2017.
-
Operating income for the first quarter of fiscal 2018 was $33.1 million, or 25.0% operating margin, compared to $21.2 million, or 20.6% operating margin in the prior year period.
-
First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, which benefited from the adoption of a new accounting standard that required $16.8 million, or $0.37 per diluted share, of excess tax benefits related to employee share-based compensation awards be recorded as a reduction of income tax expense. This compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period, before new accounting standards.
-
The Company generated $12.0 million in cash, cash equivalents and marketable securities, totaling $289.1 million as of June 30, 2017, compared to $277.1 million at March 31, 2017. The Company incurs annual cash outlays in the first quarter and currently has no debt.
-
The Company has recently received approval from the Japanese Ministry Health Labour and Welfare (MHLW) for reimbursement on Impella 2.5 and 5.0 Impella heart pumps and 10 physician societies have completed the hospital guidance document. At recent average exchange rates, reimbursement in Japan is estimated to be $24,000, equivalent to our Impella sales price in the U.S., and commences this September. We expect our first Japanese patient in September and are reiterating our controlled Impella launch at 10 hospitals by end of this fiscal year in March.
-
On June 30, a new study of Abiomed's Impella 2.5 heart pump demonstrated potential survival benefit with pre-PCI insertion in heart attacks with the left main coronary artery.
"We have been notified by MHLW of Japanese reimbursement for Impella beginning in September allowing our introduction into the world's second largest medical device market," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "Our continued execution validates Abiomed as one of the fastest growing medical technology companies with increasing GAAP profitability and no debt. I am proud of our team's ability to consistently achieve our strategic initiatives and execute on our tactical plan as Abiomed builds the Field of Heart Recovery."
FISCAL YEAR 2018 OUTLOOK
The Company is increasing the lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $560 million to $575 million, an increase in revenue of 26% to 29% from the prior year. This compares to the prior forecast of $555 million to $575 million. The Company is maintaining its fiscal year guidance for GAAP operating margin in the range of 22% to 24%.
CONFERENCE CALL
The Company will host a conference call to discuss the results on Thursday, July 27, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EDT July 27, 2017 through 11 a.m. EDT on July 30, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 51159965.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Abiomed, Inc. and Subsidiaries | ||||||||
Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
(in thousands, except share data) | ||||||||
June 30, 2017 | March 31, 2017 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 43,970 | $ | 39,040 | ||||
Short-term marketable securities | 207,441 | 190,908 | ||||||
Accounts receivable, net | 53,557 | 54,055 | ||||||
Inventories | 36,926 | 34,931 | ||||||
Prepaid expenses and other current assets | 9,021 | 8,024 | ||||||
Total current assets | 350,915 | 326,958 | ||||||
Long-term marketable securities | 37,669 | 47,143 | ||||||
Property and equipment, net | 92,804 | 87,777 | ||||||
Goodwill | 33,199 | 31,045 | ||||||
In-process research and development | 15,487 | 14,482 | ||||||
Long-term deferred tax assets, net | 113,457 | 34,723 | ||||||
Other assets | 8,686 | 8,286 | ||||||
Total assets | $ | 652,217 | $ | 550,414 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 12,784 | $ | 20,620 | ||||
Accrued expenses | 35,695 | 37,703 | ||||||
Deferred revenue | 9,697 | 10,495 | ||||||
Current portion of capital lease obligation | 829 | 799 | ||||||
Total current liabilities | 59,005 | 69,617 | ||||||
Other long-term liabilities | 588 | 3,251 | ||||||
Contingent consideration | 9,418 | 9,153 | ||||||
Long-term deferred tax liabilities | 837 | 783 | ||||||
Capital lease obligation, net of current portion | 15,325 | 15,539 | ||||||
Total liabilities | 85,173 | 98,343 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Class B Preferred Stock, $.01 par value | - | - | ||||||
Authorized - 1,000,000 shares; Issued and outstanding - none | ||||||||
Common stock, $.01 par value | 441 | 437 | ||||||
Authorized - 100,000,000 shares; Issued - 45,791,680 shares at June 30, 2017 and 45,249,281 shares at March 31, 2017 | ||||||||
Outstanding - 44,080,941 shares at June 30, 2017 and 43,673,286 shares at March 31, 2017 | ||||||||
Additional paid in capital | 580,017 | 565,962 | ||||||
Retained earnings (accumulated deficit) | 65,661 | (46,959 | ) | |||||
Treasury stock at cost - 1,710,739 shares at June 30, 2017 and 1,575,995 shares at March 31, 2017 | (64,567 | ) | (46,763 | ) | ||||
Accumulated other comprehensive loss | (14,508 | ) | (20,606 | ) | ||||
Total stockholders' equity | 567,044 | 452,071 | ||||||
Total liabilities and stockholders' equity | $ | 652,217 | $ | 550,414 | ||||
Abiomed, Inc. and Subsidiaries | ||||||||
Consolidated Statements of Operations | ||||||||
(Unaudited) | ||||||||
(in thousands, except per share data) | ||||||||
Three Months Ended
June 30, |
||||||||
2017 | 2016 | |||||||
Revenue: | ||||||||
Product revenue | $ | 132,431 | $ | 102,989 | ||||
Funded research and development | 37 | 6 | ||||||
132,468 | 102,995 | |||||||
Costs and expenses: | ||||||||
Cost of product revenue | 21,862 | 15,070 | ||||||
Research and development | 16,931 | 15,660 | ||||||
Selling, general and administrative | 60,597 | 51,032 | ||||||
99,390 | 81,762 | |||||||
Income from operations | 33,078 | 21,233 | ||||||
Other income: | ||||||||
Investment income, net | 635 | 269 | ||||||
Other income (expense), net | 79 | (77 | ) | |||||
714 | 192 | |||||||
Income before income taxes | 33,792 | 21,425 | ||||||
Income tax (benefit) provision (1) | (3,582 | ) | 8,515 | |||||
Net income | $ | 37,374 | $ | 12,910 | ||||
Basic net income per share | $ | 0.85 | $ | 0.30 | ||||
Basic weighted average shares outstanding | 43,895 | 42,811 | ||||||
Diluted net income per share (2) | $ | 0.82 | $ | 0.29 | ||||
Diluted weighted average shares outstanding | 45,608 | 45,178 | ||||||
(1) Income tax provision includes the effect of the following item: | ||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 16,842 | $ | - | ||||
(2) Diluted net income per share includes the effect of the following item: | ||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 0.37 | $ | - | ||||
* In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required. | ||||||||
For further information please contact:
Ingrid Goldberg Ward
Director, Investor Relations
978-646-1590
ir@abiomed.com
Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Danske Bank A/S, ledende medarbejderes transaktioner23.4.2024 09:20:22 CEST | pressemeddelelse
23. april 2024 Indberetning nr. 41/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024.04.22
Danske Bank A/S, transactions by persons discharging managerial responsibilities23.4.2024 09:20:22 CEST | Press release
23 April 2024 Notification no. 41/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024.04.22
Sista dag för handel med uniträtter i Cortus Energy23.4.2024 09:06:04 CEST | Pressemelding
Stockholm, den 23 april 2024 PRESSMEDDELANDE EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. Idag, den 23 april 2024, är sista dag för handel med uniträtter som utfärdades i samband med Cortus Energy AB:s (”Cortus Energy” eller ”Bolaget”) företrädesemission av units, som beslutades av styrelsen den 29 februari 2024 och som godkändes av extra bolagsstämma den 2 april 2024 (”Företrädesemissionen”). Uniträtter som ej nyttjas för teckning eller avyttras förfaller värdelösa. Villkor och tidplan för Företrädesemissionen För varje innehavd aktie på avstämningsdagen den 4 april 2024 tilldelades innehavaren en (1) uniträtt. En (1) uniträtt
Semiconductor Tech Firm IceMOS Technology One of Only Ten Exceptional Exporters Honoured in UK Government’s Made in the UK, Sold to the World Awards23.4.2024 09:00:00 CEST | Press release
IceMOS Technology recognized as award winner in Advanced Manufacturing & Construction category in 2024 Department for Business and Trade’s (DBT) Made in the UK, Sold to the World AwardsNow in its second year, the awards celebrate outstanding small and medium businesses achieving exporting successIceMOS Technology recognized for its manufacturing expertise, has a manufacturing centre of excellence in Belfast, with 99% of its business exported outside of the British Isles LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Semiconductor technology firm, IceMOSTechnology Corporation today announced it is among the 2024 winners of the Department for Business and Trade’s (DBT) Made in the UK, Sold to the World Awards announced today. Now in its second year, the awards celebrate the international sales success of small and medium businesses across the UK and provide a stepping stone for further growth and opportunity. Recognized in the Advanced Manufacturing & Construction category, IceMOS Technology
PolyPlank AB: Delårsrapport Januari-Mars 202423.4.2024 09:00:00 CEST | Pressemelding
Vd har ordet Den 1 mars 2024 tillträdde jag som ny vd i PolyPlank. Jag har arbetat på PolyPlank sedan 2008 och efter 2011 som ekonomichef. Därför är jag väl insatt bolaget och de satsningar samt neddragningar som gjorts för att anpassa sig till rådande konjunktur. Omsättningen för kvartalet uppgår till 6,2 MSEK (10,3), rörelseresultatet uppgår till -0,9 MSEK (-0,9). Tack vare minskade personalkostnader och övriga externa kostnader genom de åtgärder vi vidtog under andra halvåret 2023 kan vi hålla nere förlusten. Resultatet före avskrivningar (EBITDA) är positivt. Vi jobbar aktivt med att minska vårt lager och frigöra likviditet, från 2023-03-31 till 2024-03-31 har vi minskat lagret med 3,7 MSEK. Våra leveranser av hylsplugg är inte lika drabbade av konjunkturen som våra produkter till fastighetssektorn. Den försäljningen ligger på samma nivå som 2023. Under första kvartalet har vi levererat och monterat ett bullerplank i Rälla på 2,2 MSEK. Extra trevligt att få förtroendet på vår egna